



Minutes
The Scottish Terrier Club of America, Inc.
Meeting of the Officers and Directors
Teleconference
Wednesday April 18, 2018
8:30 p.m. – 10:01 p.m.

PRESENT: President, Lori Kelly; Vice President, Pam Williams, Corresponding Secretary, Theresa Thomas, Recording Secretary, Kathleen Ferris, Treasurer, Steve Russell; AKC Delegate, Helen Prince, Directors: Class of 2018: Jerry Burge, Ron McConnell, Sonya Neve, Pat Wooster. Class of 2019: Kelli Edell, Michael Krolewski, Janet Tomlinson, Pam Wilson

Roll Call

Welcome – L Kelly

Approval of Meeting Minutes

March 21, 2018 approved as submitted

Reports of the Secretaries

Corresponding

HTF Correspondence - Grants (2) – see attached

T.Thomas shared a request for approval for 2 grants from the HTF with the BOD prior to the meeting so that everyone could read and understand the requests.

Motion to approve Grant #2500: Immune Targeting of the V600E B-Raf Neoantigen in Canine Urothelial Carcinoma the Grant in the Amount of \$25,000. Neve/Edell. Passed unanimously.

Motion to approve Grant# 02510: Identification of Novel Synthetic Lethal Partners to Optimize PI3K Targeted Therapies in Canine Hemangiosarcoma the Grant will be for \$5,000. Neve/Edell. Passed unanimously.

Recording None

Treasurer's Report

End of Month Summary – see online

S.Russell presented an overview that follows at the end of the minutes.

Vice President's Report

Rotating 2020 Contract/Venue/Host Hotel

P.Williams starting to finalize arrangements with the Roberts Center for March 19 -22, 2020. Overview on costs. Approval of expenses by consensus.

MCKC National Specialty 2018

A fun component for the Thursday night program was discussed. P.Williams and L.Kelly presented idea for possible programming based on event L.Kelly attended at Sheraton with fellow vendors. More research to be completed. P.Williams explained that a program for Saturday is being explored. Discussion on program offered by Carol Vaseleski. Possible dinner on Saturday.

Old Business

Cooke/Berry Trophy

L.Kelly reported on her communications with Cindy. **Motion to decline the award offered by C.Cooke/W.Berry. Neve/Krowleski.** Discussion followed regarding automated tallying. **Motion to table Prince/Tomlinson. Passed unanimously.**

Website Template

L.Kelly reported that K.Prokopetz was not ready. Discussion to be re-scheduled for next meeting.

Master of Barn Hunt Award

L.Kelly asked M.Krolewski to add to website. Discussion of location and wording.

New Business

STC Western VA status

H.Prince reported that club is working to revitalize membership and to move club to North Carolina. AKC will require a membership list and application to proceed with renaming club. Name to be determined. Specialty will be held this year; a Nov. '18 date was requested. **Motion to allow STCWV to hold their show on November 10 or 11, 2018. Prince/Tomlinson. Passed unanimously.**

STC Greater Louisville Request -Date Change

Discussion needed regarding STCGL request for a date change. L.Kelly asked each member to provide their opinion, one at a time in favor or not in favor of change of date. **Motion to approve the STCGL's request to move their specialty date from August to mid-March to go into effect 2019. Prince/Neve. Passed by roll call 12 yes – 1 no. P.Williams no, T.Thomas yes, K.Ferris - yes, S.Russell yes, H.Prince yes, J.Burge yes, R.McConnell yes, S.Neve yes, P.Wooster yes, K.Edell yes, M.Krolewski yes, J.Tomlinson yes, P.Wilson yes.**

Request from Janet Tomlinson for the Pedigree Database

Motion to approve an increase to the budget of the pedigree database committee to \$500 for 2018. Edell/Williams. Passed unanimously.

Next Meeting May 16, 2018 at 8:30 pm

Motion to adjourn 10:01 Ferris/Neve. Passed unanimously.

Respectfully Submitted – Kathleen Ferris, Recording Secretary

Dear Theresa,

Apologies for resending this email, but please share this corrected version with the Board members and discard the former email.

On behalf of the HTF, I am writing to request Board approval for funding of two research projects. Both of these projects are with the AKC Canine Health Foundation, and we believe they both carry great promise for the health of our Scotties.

1. Grant #2500: Immune Targeting of the V600E B-Raf Neoantigen in Canine Urothelial Carcinoma

Grant Amount: \$183,146

Dr. Nicola J Mason, BVetMed, PhD, Trustees of the University of Pennsylvania

February 1, 2018 - January 31, 2020

Breed(s): -All Dogs

Research Program Area: Oncology

Dr. Mason's research carries the study of TCC to the next level of therapy with immunotherapy. In this study, Dr Mason will be targeting the B-RAF mutation which we now know is present in up to 87% of cases of TCC in dogs. I am attaching the lay abstract for you to read over:

Abstract

Bladder cancer or urothelial carcinoma (UC) affects approximately 40,000 dogs per year in the US with specific breeds including Scottish Terriers, West Highland White Terriers, Shetland Sheepdogs, Beagles, and Parson Russell Terriers being over-represented. Affected dogs usually display lower urinary tract clinical signs including bloody urine, frequent urination, difficulty and pain on urinating, and urinary outflow tract obstructions. Standard of care consists of anti-inflammatory drugs either alone or in combination with chemotherapy or radiation therapy. While these treatments can lead to stable disease for 6-12 months, they rarely lead to a cure, and most dogs eventually succumb to their disease. In human medicine, urinary bladder tumors have been shown to exhibit a high gene mutational burden which directly correlates with a favorable response to immune therapies. Canine UC exhibits a similar mutational load suggesting that the disease in dogs may also be immune responsive. In this study, the investigators will evaluate the safety and effectiveness of a novel targeted, immune therapy that aims to promote a powerful immune response against a specific gene mutation (V600E B-Raf) recently identified in up to 87% of dogs with UC. The investigators hypothesize that vaccine-induced anti-tumor immune responses will lead to tumor regression and that such favorable responses will correlate with the baseline mutational burden of the tumor. The investigators will use standard immunological methods and advanced genetic sequencing technology to study systemic and intra-tumoral immune responses to identify biomarkers that may predict immunological and clinical response in dogs.

Collaborative grant between the AKC Canine Health Foundation and the V Foundation for Cancer Research.

The HTF voted to donate \$25,000 in support of this study.

2. Grant# 02510: Identification of Novel Synthetic Lethal Partners to Optimize PI3K Targeted Therapies in Canine Hemangiosarcoma

Principal Investigator: Cheryl London, DVM PhD; Tufts Medical Center

Hemangiosarcoma is an increasingly identified killer of Scotties, although the exact prevalence of this deadly cancer is not fully known. Many times the disease presents itself as sudden death in a Scottie, and necropsies are rarely done at such a devastating time. The HTF is dedicated to supporting research in this cancer and we have elected to support another project looking into immunotherapy. Below is the lay abstract for this study:

Hemangiosarcoma (HSA) is a cancer of the cells lining the blood vessels that is very aggressive and has nearly always spread by the time it is diagnosed. HSA accounts for 5-7% of all cancers in dogs resulting

in approximately 25-50,000 new cases per year. The treatment of choice is surgical removal followed by chemotherapy administration. Unfortunately, despite aggressive therapy, the majority of dogs diagnosed succumb to their disease within 6-8 months. Virtually no improvements in outcome for affected dogs have occurred in the past 30 years despite multiple clinical trials and research efforts. More recently a new therapy has been developed targeting two receptors on HSA cells. However, the majority of dogs still died, by 10-12 months after treatment. The molecular pathway known as the PI3K/AKT/mTOR pathway has previously been implicated in the pathogenesis of many forms of cancer including HSA. Indeed, inhibitors of PI3K/AKT/mTOR pathway have some activity against HSA cell lines in the laboratory. The investigators have generated data showing that a subset of canine HSA tumors possess genetic mutations in PI3K that are known to activate the pathway in cancer cells. In this study, they will fully characterize the expression and function of PI3K in canine HSA tumor cell lines and tumor samples. This information will then be leveraged to identify new ways to block the PI3K/AKT/mTOR pathway using a combination of small molecule inhibitors that are most effective at

killing tumor cells. These data will then be used to design future clinical trials in dogs with HSA.

The HTF has voted to donate \$5000 in support of this study. At this time, the AKC is matching funds with all hemangiosarcoma research donations, so the HTF's donation will in effect be doubled to \$10,000.

Thank you,

Marcia Dawson
Chair, STCA HTF

April 18, 2018

Treasurer's Report to Board

Financial Report (March)

March reports were posted on the Board list on April 1st under Files/Treasurer.
The **Club lost -\$7,094 in March**, due to the timing of expenses for Rotating.

2018 National Rotating Specialty (see separate report):

Show resulted in a net profit of +\$973 (\$12,116 income - \$11,143 expense).

Successful Top 20 surplus of \$1,381 (\$3,563 income - \$2181 expense).

Generous Trophy Donations surplus of \$874 (\$1,798 income - \$923 expense).

Offsetting \$0 return from HASTC & Bell City KC for STCA Specialty at Purina.

Also, the B&W Agility Trial returned \$1,000 revenue to the STCA.

Financial Reports (Mid-April)

The **Club has lost -\$3,510 in April**, due to the timing of expenses for Bagpiper 2018#1.

Income

Bagpiper 2018#2 Ads \$3,845

Investment Earnings \$2,410

Boutique \$710

Expense

Bagpiper 2018#1 -\$8,872 (income of \$12,105 resulted net profit of \$3,233)

Boutique Inventory \$681

Investments (see separate report):

Surplus cash is invested in a ladder of CDs at Stifel with 1,2,3,4,5&10 yr maturities

Pays earnings each 6 months (April & October)

Paid \$2,410 in April 2018

Maturing CD was re-invested in another 5-year CD to maintain ladder.

Due to rising interest rates, maturing CD 1.05% interest replaced with 3% interest.

Projected annual income from investments is now **\$5,399**

Year-to-Date

P&L YTD stands at +\$2,542

Versus +\$17,110 surplus at the same date in 2017

P&L YTD has decreased \$14,568 (\$3,005 less income and \$10,161 more expense).

Balance Sheet Assets stand at **\$489,464**

Steve Russell
STCA Treasurer